Conference Reports

Hong Kong
19 October 2019 - 20 November 2019
22 November 2019 - 24 November 2019
Hong Kong
21 September 2019 - 21 September 2019
Barcelona
27 September 2019 - 01 October 2019
Amsterdam
13 June 2019 - 16 July 2019
Chicago, Illinois, US
31 May 2019 - 04 June 2019
Geneva, Switzerland
10 April 2019 - 13 April 2019
Atlanta, Georgia
29 March 2019 - 03 April 2019
16 March 2019 - 17 March 2019
San Francisco, California
14 February 2019 - 16 February 2019
19 January 2019 - 20 January 2019
San Francisco, California
17 January 2019 - 19 January 2019
San Antonio, Texas
04 December 2018 - 08 December 2018
San Diego, California, US
01 December 2018 - 04 December 2018
Singapore
23 November 2018 - 25 November 2018
Kuala Lumpur
22 November 2018 - 25 November 2018
Munich
19 October 2018 - 23 October 2018
Kuala Lumpur
01 October 2018 - 04 October 2018
Amsterdam, the Netherlands
23 July 2018 - 27 July 2018
Stockholm, Sweden
14 June 2018 - 17 June 2018
Chicago, Illinois
01 June 2018 - 05 June 2018
05 May 2018 - 06 May 2018
Chicago, Illinois, US
14 April 2018 - 18 April 2018
Geneva
11 April 2018 - 14 April 2018
Barcelona, Spain
21 March 2018 - 23 March 2018
Copenhagen
16 March 2018 - 19 March 2018
San Francisco, California
08 February 2018 - 10 February 2018
San Francisco, California, US
18 January 2018 - 20 January 2018
Hong Kong
20 January 2018 - 20 January 2018
Atlanta, Georgia, US
09 December 2017 - 12 December 2017
San Antonio, Texas, US
05 December 2017 - 09 December 2017
Singapore
17 November 2017 - 19 November 2017
San Diego, California, US
24 September 2017 - 27 September 2017
Madrid, Spain
08 September 2017 - 12 September 2017
Madrid
22 June 2017 - 25 June 2017
Chicago, Illinois, US
02 June 2017 - 06 June 2017
Geneva
05 May 2017 - 08 May 2017
Orlando, Florida
16 February 2017 - 18 February 2017
Amsterdam
27 January 2017 - 30 January 2017
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 02 Jan 2020

Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.